Back to Search
Start Over
The emerging role of psilocybin and MDMA in the treatment of mental illness.
- Source :
- Expert Review of Neurotherapeutics; Dec2020, Vol. 20 Issue 12, p1263-1273, 11p
- Publication Year :
- 2020
-
Abstract
- Mental illness has a chronic course of illness with a number of clinical manifestations. Affected individuals experience significant functional, emotional, cognitive, and/or behavioral impairments. The growing prevalence of mental illness has been associated with significant social and economic costs. Indeed, the economic burden of mental illness is estimated to exceed $1.8 trillion USD over the next 30 years. A significant number of individuals affected by mental illness fail to respond to first-line treatment options. Therefore, there remains an unmet need for rapidly attenuating therapeutic options for mental health disorders with minimal social and economic burden. The paucity of novel treatment options warrants a renewed investigation of psychedelic-based psychotherapy. Herein, the authors will evaluate the therapeutic potential of traditional psychedelics, psilocybin, and MDMA, in the treatment of mental illness with a narrative review of available literature. Psychedelics, such as psilocybin and MDMA, offer an alternative avenue of therapy for many mental health disorders. Available evidence indicates that psychedelics may offer a single-dose, rapid effect model that have robust effects with treatment-resistant mental disorders and a unique advantage as a possible monotherapy for mental illness. Novel clinical trials that evaluate the safety, tolerability, and efficacy in clinically representative populations are warranted. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 14737175
- Volume :
- 20
- Issue :
- 12
- Database :
- Complementary Index
- Journal :
- Expert Review of Neurotherapeutics
- Publication Type :
- Academic Journal
- Accession number :
- 147601510
- Full Text :
- https://doi.org/10.1080/14737175.2020.1826931